BioLife Solutions Q4 revenue $22.7M (+31% YoY); guides 2025 up 16-20%

BIOLIFE SOLUTIONS INC

Q4 total revenue $22.7M (up 31% YoY); Cell Processing $20.3M (+37% YoY).
GAAP net loss from continuing ops $2.0M vs $7.2M YoY; adjusted EBITDA $4.0M (18% of revenue).
Completed sales of SciSafe and CBS in Nov 2024 for ~$79.1M total cash; cash and marketable securities $109.2M.
2025 revenue guidance $95.5-99.0M (growth 16-20%); Cell Processing $86.5-89.0M (growth 18-21%).
Cumulative 769 FDA Master File cross-references; biopreservation media in 17 approved cell/gene therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.